Osteoporosis
Conditions
Interventions
Fitness Qigong "Strengthening Bones Routine" Group:Fitness Qigong "Strengthening Bones Routine" Exercise
Regular Walking Control Group:Walking Exercise
Sponsors
Huqiao Road Community Health Service Center, Gulou District, Nanjing
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: Aged 50-80 years with assessed bone mass reduction or osteoporosis. Ultrasound-based bone density testing indicates bone mass reduction or osteoporosis (e.g., T-score less than or equal to -1.0, meeting criteria for bone mass reduction or below), accompanied by clinical features consistent with primary osteoporosis. Able to walk independently and manage basic daily activities. Cognitively alert with generally normal cognitive function, able to understand and sign informed consent, and willing to fully participate in the study process. This includes attending fitness qigong or walking exercises as scheduled, attending regular follow-ups, undergoing blood tests, and participating in ultrasound examinations. No severe mental disorders or major depression that could impair compliance. No significant cognitive impairment (e.g., moderate to severe dementia).
Exclusion criteria
Exclusion criteria: Patients with severe cardiovascular or cerebrovascular diseases (such as recent myocardial infarction, uncontrolled severe arrhythmia, acute phase of stroke, etc.), severe respiratory diseases (such as severe chronic obstructive pulmonary disease, respiratory failure, etc.), or severe hepatic or renal insufficiency that significantly impair exercise tolerance and pose a threat to life safety. Individuals with severe secondary diseases affecting bone metabolism (e.g., hyperthyroidism, Cushing's syndrome, parathyroid dysfunction) or those who have recently undergone prolonged, regular use of medications affecting bone metabolism (e.g., systemic glucocorticoids, high-dose antiepileptic drugs, immunosuppressants). Individuals with neurological or musculoskeletal disorders severely impairing lower limb mobility, such as advanced Parkinson's disease, severe sequelae of cerebral infarction, significant lower limb joint deformities, recent recovery from lower limb joint replacement surgery, or acute/unstable fractures. Individuals currently taking or planning to take anti-osteoporosis medications (e.g., bisphosphonates, denosumab, teriparatide, selective estrogen receptor modulators) within the past 6 months and unable to discontinue them. Participation in other interventional clinical studies or trials that may affect bone metabolism or motor function, or recent completion of such trials while still in the follow-up period or residual drug effect phase. Severe visual or hearing impairment preventing effective communication with investigators or understanding instructions even with corrective measures or assistive devices, such as inability to clearly see movement demonstrations or comprehend verbal guidance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Procollagen I N - terminal Propeptide; | — |
Secondary
| Measure | Time frame |
|---|---|
| Procollagen I N - terminal Propeptide;Serum C-terminal Cross-linked Telopeptide of Type I Collagen;Bone Mineral Density;Muscle Strength;Timed Up and Go test;Single-leg stance test;Visual analogue scale;Quality of Life; | — |
Countries
China
Contacts
Public ContactYunchuan Wu
Nanjing University of Chinese Medicine
Outcome results
None listed